Publications by authors named "Bobbie Graham"

Claim this Profile
E
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
Christine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, Bobbie Graham, Carmelita G Alvero

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Maxensia Owor, Camlin Tierney, Lauren Ziemba, Renee Browning, John Moye, Bobbie Graham

Pediatr Infect Dis J· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Paul Krogstad, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley, Bobbie Graham

J Pediatric Infect Dis Soc· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.
Diana F Clarke, Jos Lommerse, Edward P Acosta, Mae P Cababasay, Jiajia Wang, Bobbie Graham

J Acquir Immune Defic Syndr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Diana F Clarke, Edward P Acosta, Mae Cababasay, Jiajia Wang, Anne Chain, Bobbie Graham

J Acquir Immune Defic Syndr· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Rolando M Viani, Theodore Ruel, Carmelita Alvero, Terry Fenton, Edward P Acosta, Bobbie Graham

J Pediatric Infect Dis Soc· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults.
Nathan John Hanan, Mary Elizabeth Paul, Yanling Huo, Suad Kapetanovic, Elizabeth Smith, Bobbie Graham

Front Pediatr· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Sharon Nachman, Carmelita Alvero, Hedy Teppler, Brenda Homony, Anthony J Rodgers, Bobbie L Graham

Lancet HIV· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
Liusheng Huang, Vincent Carey, Jane C Lindsey, Florence Marzan, David Gingrich, Bobbie Graham

PLoS One· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Tim R Cressey, Ram Yogev, Andrew Wiznia, Rohan Hazra, Patrick Jean-Philippe, Bobbie Graham

J Pediatric Infect Dis Soc· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.
Ann J Melvin, Grace Montepiedra, Lisa Aaron, William A Meyer, Hans M Spiegel, Bobbie Graham

Pediatr Infect Dis J· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.
Tim R Cressey, Rohan Hazra, Andrew Wiznia, Marc Foca, Patrick Jean-Philippe, Bobbie Graham

Pediatr Infect Dis J· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
Marc Foca, Ram Yogev, Andrew Wiznia, Rohan Hazra, Patrick Jean-Philippe, Bobbie Graham

Pediatr Infect Dis J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Kajal B Larson, Tim R Cressey, Ram Yogev, Andrew Wiznia, Rohan Hazra, Bobbie Graham

J Pediatric Infect Dis Soc· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
Sharon Nachman, Carmelita Alvero, Edward P Acosta, Hedy Teppler, Brenda Homony, Bobbie Graham

J Pediatric Infect Dis Soc· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.
Matthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, Larissa Wenning, Hedy Teppler, Bobbie Graham

J Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Richard M Rutstein, Pearl Samson, Terry Fenton, Courtney V Fletcher, Jennifer J Kiser, Bobbie Graham

Pediatr Infect Dis J· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Sharon Nachman, Nan Zheng, Edward P Acosta, Hedy Teppler, Brenda Homony, Bobbie Graham

Clin Infect Dis· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Jennifer R King, Ram Yogev, Patrick Jean-Philippe, Bobbie Graham, Andrew Wiznia

Antimicrob Agents Chemother· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
Jennifer J Kiser, Richard M Rutstein, Pearl Samson, Bobbie Graham, Grace Aldrovandi

AIDS· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study.
Patricia A Garvie, Patricia M Flynn, Marvin Belzer, Paula Britto, Chengcheng Hu, Bobbie Graham

J Adolesc Health· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead.
Aditya H Gaur, Marvin Belzer, Paula Britto, Patricia A Garvie, Chengcheng Hu, Bobbie Graham

AIDS Res Hum Retroviruses· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
Jennifer R King, Edward P Acosta, Ram Yogev, Andrew Wiznia, Joyce Kraimer, Bobbie Graham

Pediatr Infect Dis J· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
Courtney V Fletcher, Jaime G DeVille, Pearl M Samson, John H Moye, Joseph A Church, Bobbie Graham

J Allergy Clin Immunol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
William T Shearer, Jaime G DeVille, Pearl M Samson, John H Moye, Courtney V Fletcher, Bobbie Graham

J Allergy Clin Immunol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis